Search
Temocapril
go.drugbank.com/drugs/DB08836InvestigationalTemocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalOne of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).
Midecamycin
go.drugbank.com/drugs/DB13456Investigational[A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791]
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBMN-351
go.drugbank.com/drugs/DB18186InvestigationalIt is under investigation for the treatment of Duchenne Muscular Dystrophy (DMD). … BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.
Insulin efsitora alfa
go.drugbank.com/drugs/DB19013InvestigationalBasal Insulin for the First Time (QWINT-1)). … Insulin efsitora alfa is under investigation in clinical trial NCT05662332 (A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting
Lercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnLercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Deanol
go.drugbank.com/drugs/DB13352InvestigationalDeanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsIP501
go.drugbank.com/drugs/DB06450ExperimentalIP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis. … The compound was developed by Indevus Pharmaceuticals.
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.